Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Labelled Comp Radiopharm. 2018 Mar 12;61(9):727–738. doi: 10.1002/jlcr.3605

Figure 5. Predictive Markers of Treatment.

Figure 5

Time-to-treatment failures were evaluated based on HER2-PET/CT A), early FDG-PET/CT B) and combination of both HER2- and FDG-PET/CT C). This research was originally published in Ann Oncol. Gebhart G, Lamberts LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27(4):619–624. (Reproduced with permission From Oxford University Press Ref. 63).